Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 1—January 2012

CME ACTIVITY

Accelerating Control of Pertussis in England and Wales

Helen CampbellComments to Author , Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy G. Harrison, and Elizabeth Miller
Author affiliations: Health Protection Agency, London, UK

Main Article

Table 6

Effectiveness of pertussis vaccine among pertussis-infected infants 9 weeks to <6 months of age, England, 2002–2009*

No. doses received before disease onset No. vaccinated case-patients/total no. (%)† Average % coverage in comparable population† % VE (95% CI)
1 174/428 (41) 64 62 (53–69)
2 36/91 (40) 82 85 (77–91)
3 5/24 (21) 84 95 (86–99)

*Data are for culture-, PCR-, and serology-confirmed cases with onset during 2002–2009. Case-patients received 1 of the following 3 vaccine regimens: 1) DTwP (diphtheria/tetanus/whole-cell pertussis) or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; 2) DTwP at 2, 3, and 4 mo of age; or 3) DTaP5 at 2, 3, and 4 mo of age. VE, vaccine effectiveness.
†Coverage for 1, 2, and 3 doses was calculated by using the number of doses received or 0 doses. Note that case-patients with 0 doses may be counted in >1 group.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO